By Staff Reports
(Victor Valley)– Recent years have provided the healthcare community with a brand new perspective on the enduring dilemma of how to treat pain effectively. As a recent article in Pain Medicine News points out, the proper treatment of pain is likely to involve well-trained providers who are versed in a multidisciplinary approach to solving the problem.
To a large extent, notes the magazine, the complexity of solving this problem is due to the fact that no single pain management technique has been shown capable on its own of providing reliable pain control. Neither opioid medications, nor antidepressants, nor traditional physical therapy, nor alternative treatments have been proven completely able to achieve this goal. As a result, the state of the field of pain medicine is in a state of great flux.
“There is no doubt that creativity and flexible thinking will be crucial tools going forward in the world of pain medicine,” says Anthony P. Mack, CEO of Virpax Pharmaceuticals. “But there is reason for hope in the form of encouraging studies that could provide the innovation that is needed in this area.”
Virpax™ is proving itself as a formidable competitor in the field. The company is developing its compound DSF100, an investigational spray film that is designed to deliver an NSAID (non-steroidal anti-inflammatory drug) through the skin via a metered-dose spray. The product adheres well to the skin and dries quickly. The unique Patch-in-a-Can™ technology offers the possibility of long-term dosing of a product through the skin or mucosal membrane from a clear “patch” conveniently applied as a spray from a cannister. The company intends to advance the product in clinical studies.
Thinner than a standard liquid bandage, the aerosol spray is invisible. It can be configured for an immediate-release or extended formulation, so a drug can be delivered either at once or over a span of time that can range from 12 to 48 hours. As a spray, this formulation manages to avoid the mess of creams or gels that can be rubbed off by clothing or physical contact.
At the same time, the company’s first investigational product, LBL100, is a potentially long-acting local anesthetic that will be studied to treat post-operative pain. It may have the potential to reduce moderate-to-severe post-operative pain for at least 96 hours.
LBL100 delivers an anesthetic in a unique way—by enclosing it inside structures known as liposomes, which are made out of lecithin and cholesterol. The liposomes themselves are embedded into tiny beads that form a substance called a lipogel. The system delivers medicine that is designed to provide pain relief relatively quickly and for a relatively long period of time.
“These unique delivery methods are currently being studied to see if they have the potential to reduce patients’ reliance on opioid painkillers, improve the quality of care and help reduce the overall cost of care as well,” Mack adds.